AUPH | Aurinia Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.65 - 9.04
52 Week Range	4.71 - 9.74
Beta	1.77
Implied Volatility	57.31%
IV Rank	13.77%
Day's Volume	1,562,963
Average Volume	1,237,223
Shares Outstanding	143,179,000
Market Cap	1,268,565,940
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-09-03

Valuation
Profitability
Growth
Health
P/E Ratio	-59.07
Forward P/E Ratio	N/A
EPS	-0.15
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	300
Country	Canada
Website	AUPH

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

AUPH's peers: VKTX, AXSM, MDGL, IMGN, MCRB, EXEL, TGTX, BTAI, SRPT, HEPA, PTCT, ICPT, TERN, AKRO, RETA

*Chart delayed

Analyzing fundamentals for AUPH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see AUPH Fundamentals page.

Watching at AUPH technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AUPH Technicals page.